Transcatheter arterial embolization (TAE) is widely accepted as a nephron-sparing, minimally invasive treatment for renal angiomyolipoma (AML), particularly in symptomatic patients and those with large lesions or high-risk vascular features such as intratumoral aneurysms. As embolization devices and microcatheter techniques have advanced, TAE has become an increasingly preferred alternative to surgery in selected cases. Nevertheless, a critical question persists: which embolic material or procedural approach best achieves durable tumor control while maintaining an acceptable safety profile?

This lack of consensus is unsurprising. AML is a heterogeneous entity with variable proportions of adipose tissue, smooth muscle, and abnormal vasculature, and embolization practice varies considerably across institutions with respect to material selection, endpoint definition, and adjunctive techniques. Comparative studies are further constrained by small sample sizes, single-center designs, and inconsistent outcome metrics. Against this backdrop, the dual-center retrospective cohort study by Kim et al. [1] offers timely and valuable evidence, comparing ethanol-based embolization with polyvinyl alcohol (PVA) particle embolization and evaluating the incremental effect of microcoil use within ethanol-based therapy.

The investigators analyzed 119 adult patients with single renal AML treated between 2005 and 2023. To address baseline imbalance, they applied inverse probability treatment weighting using age, sex, and baseline tumor volume, followed by linear mixed-effects modeling for longitudinal volume change. Tumor response was assessed volumetrically using an ellipsoid formula derived from three orthogonal diameters on CT or MRI. The authors report that ethanol-based embolization achieved higher response rates (≥50% volume reduction) than PVA (92.1% vs. 78.4%), and that ethanol combined with microcoils demonstrated superior response and lower recurrence compared with ethanol alone. These findings suggest that ethanol-based approaches, particularly when reinforced with proximal occlusion, may offer meaningful advantages in AML embolization.

A central challenge in interpreting comparative embolization studies is procedural heterogeneity. In this study, ethanol-based embolization encompassed both ethanol-only and ethanol-plus-microcoil cases, whereas the PVA cohort consisted exclusively of PVA without coil use. This design preserves internal clarity within the PVA group but creates an important interpretive limitation: the comparison effectively becomes “ethanol ± coil” versus “PVA without coil,” rather than a fully strategy-matched analysis.

In routine practice, coils are frequently added after particulate embolization to reduce the risk of recanalization, especially in larger feeding arteries or lesions with aneurysmal components. Readers will naturally ask under what angiographic circumstances coils were added in the ethanol group. The authors note that coil use was left to operator discretion based on angiographic findings, and that PVA-plus-coil cases were excluded from the PVA group, a reasonable approach for maintaining group separation, but one that complicates interpretation, as “ethanol superiority” may in part reflect “strategy superiority”. Future studies would benefit from explicitly reporting coil selection criteria, including feeder diameter thresholds, washout patterns, residual tumor staining after distal embolization, or aneurysm and shunt physiology, so that the combined approach can be reproduced in a standardized manner.

The most thought-provoking signal in this manuscript emerges from the subgroup analysis. The ethanol-only subgroup demonstrated a response rate of 73.8%, lower than that of the PVA group (78.4%), and a higher recurrence rate (30.2% vs. 14.8%). Although these values derive from separately weighted cohorts and no direct statistical comparison was performed, the numerical pattern is suggestive and reinforces the case for the coil-stratified reanalysis proposed below. These findings raise a plausible alternative explanation: the favorable outcomes attributed to ethanol-based embolization may be driven primarily by the ethanol-plus-microcoil subgroup rather than by ethanol itself.

This is not a semantic distinction. If the principal determinant of durability is coil-supported proximal stabilization, the practical conclusion shifts: rather than recommending ethanol as a preferred agent, the emphasis should fall on a procedural framework that integrates durable proximal control with distal devascularization. The authors argue that the benefit reflects synergy between ethanol and coils rather than coil use alone, citing improved response rates (91.3% vs. 73.8%) and markedly reduced recurrence (7.1% vs. 30.2%) in the ethanol-plus-microcoil group compared with ethanol only. This explanation is clinically plausible; however, because the PVA cohort excluded coil use by design, the independent contributions of coil support and embolic agent cannot be fully disentangled.

A potentially informative supplementary analysis, if feasible, would compare a “coil group” (ethanol-plus-coil) with a “non-coil group” (ethanol-only and PVA-only combined). Even if selection bias cannot be eliminated, such a comparison would shed additional light on whether the observed advantage is primarily material-driven or strategy-driven.

Another notable contribution of this study is its presentation of a mechanistic rationale for ethanol-based embolization. As a liquid embolic agent, ethanol penetrates distal microvasculature, induces endothelial destruction and tumor necrosis, and achieves permanent occlusion at the arteriolar and capillary levels. This theoretical advantage offers a coherent basis for improved response and durability compared with particulate agents, which may occlude more proximally or incompletely.

However, ethanol-only embolization may be vulnerable to rapid washout in high-flow vessels, increasing the risk of incomplete occlusion, recanalization, and recurrence. In this context, microcoil augmentation serves as a logical procedural reinforcement: ethanol provides distal endothelial injury, while coils stabilize proximal occlusion and reduce washout, thereby prolonging contact time and improving durability. This “distal ablation plus proximal stabilization” strategy aligns with established embolization principles and plausibly explains why the ethanol-plus-microcoil subgroup achieved the most favorable outcomes.

This strategy-focused interpretation is consistent with prior experience in AML embolization. In an earlier comparative study by Jin et al. [2], embolization with ethanol-lipiodol emulsion and PVA particles showed no significant difference in shrinkage rate, with both approaches demonstrating safety and efficacy. Notably, microcoils were used selectively to treat aneurysms or proximal feeding arteries larger than 2 mm after distal embolic occlusion, in order to prevent incomplete occlusion or recanalization. Taken together, these data suggest that durable outcomes depend less on identifying a universally superior agent and more on applying a tailored strategy that integrates both distal and proximal embolization components.

Although volumetric response provides an objective endpoint, the ultimate measure of AML embolization success lies in clinically meaningful outcomes: prevention of hemorrhage, relief of symptoms, avoidance of retreatment, and preservation of renal function. Future investigations should incorporate standardized reporting of these endpoints alongside imaging response. Strategy-matched comparisons, such as PVA-plus-coil versus ethanol-plus-coil, would provide stronger evidence for true material superiority and help establish reproducible procedural algorithms.

In summary, the authors present valuable dual-center evidence suggesting that ethanol-based embolization, particularly the ethanol-plus-microcoil approach, may achieve high response rates and improved durability compared with PVA-only embolization. The broader implication is that AML embolization outcomes may be optimized when distal devascularization is paired with stable proximal control, especially in lesions with high-flow vascular physiology.

(1) Ethanol-based embolization may offer improved early response in renal AML, but outcomes should be interpreted within the context of procedural strategy, particularly the adjunctive use of microcoils. (2) When ethanol washout or high-flow feeding anatomy is anticipated, combining distal ethanol embolization with proximal coil stabilization may improve durability and reduce the risk of recurrence. (3) Future studies should incorporate AML composition and angiographic phenotype to guide individualized embolization strategies, moving beyond agent-only comparisons.

Citations to this article as recorded by